Clinical Trials
-
Principal Investigator:
Sloane Heller, MDThe purpose of this study is to understand how liver disease affects thinking and memory, both before and after transplant. Participants will take a cognitive test, which will be a series of tasks and questions similar to a video game, at home on their own computers, tablets, or phones. This will take approximately 45 minutes, and participants will do this once a year for 3 years. We will assess how thinking and memory changes over time and in response to transplant. -
Principal Investigator:
Rebecca Straus Farber, MDWe need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID-19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID-19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find... -
Principal Investigator:
Fabio M. Iwamoto, MDThe purpose of this study is to compare the effects of pembrolizumab simultaneously with the Optune device and maintenance temozolomide(TMZ) versus placebo simultaneously with Optune and maintenance TMZ for the study treatment of newly diagnosed GBM. In this study, a placebo is an inactive substance that looks the same as and is given the same way as pembrolizumab. The effects of pembrolizumab are compared to the effects of the placebo. The current United States Food and Drug Administration (FDA) approved treatment for newly diagnosed GBM includes the addition of Optune to the treatment with... -
Principal Investigator:
Philip L. De Jager, MD, PHDThe Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed... -
Principal Investigator:
Sheng-Han Kuo, MDWhy? By investigating individuals with SCA, we will gain valuable insights into the specific mechanisms through which the cerebellum participates in cognitive processes. Who? Healthy adults over the age of 18, who would like to participate as controls. What? Participation involves one clinic visit for 3-4 Hours, involving cognitive baseline measurements, an electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) recording during which a decision-making two-step task will be performed. Cost to me? There is no cost involved for participating in the study. You will receive... -
Principal Investigator:
Philip L. De Jager, MD, PHDWe're testing a new type of MRI scanner that's smaller and portable - like a mobile MRI unit. This makes it easier to provide brain scans to people who have difficulty traveling to hospitals or live far from medical centers. We'll be studying people with multiple sclerosis (MS) and similar brain conditions. Our goal is to learn how well this portable scanner can measure brain changes and how these changes relate to memory and thinking abilities. By validating this technology, we hope to make MRI scanning more accessible to everyone while advancing our understanding of conditions like MS. The... -
Principal Investigator:
Philip L. De Jager, MD, PHDThe Snapshot study aims to understand brain and spinal cord aging in healthy individuals and individuals with multiple sclerosis (MS). We aim to identify new tools that will help us to achieve successful brain aging in the general population and in people with an underlying autoimmune disease. A critical aspect of this study is that we are looking for individuals who are willing to donate their brain and spinal cord when they pass away; this will enable the investigators to understand which molecules in the brain made someone more or less likely to age successfully. The brains will be housed... -
Principal Investigator:
Philip L. De Jager, MD, PHDMS Genetics aims to better understand the genetic component of demyelinating diseases by doing genetic testing on blood samples of participants. This study involves a one-time blood draw and completion of questionnaires spread out over a couple of years in hopes to better understand the genes that makes one predisposed to Multiple Sclerosis and various other demyelinating diseases. -
Principal Investigator:
Christiane Reitz, MD, PhDWe are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on... -
Principal Investigator:
Thomas H. Brannagan III, MDThe main purpose of this study is to learn how the study drug (NMD670) works and how safe the study drug is compared with placebo. A placebo is an inactive material that looks like the study drug but does not have any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing. You will be in this study for up to 8 weeks. During the study, you will visit the study center at least 6 times. If you are eligible to participate in this study, you will be seen by a doctor with expertise in CMT care who will be leading the research study at a...